NCT07440901

Not Yet Recruiting

Remodeling of MHC-related Immune Microenvironment in MIBC Af...

Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source

Compare

Other study identifiers

Sponsor study identifier

NCC4928

Study Type

observational

Estimated enrollment

30

Locations

0 countries

Sites

N/A

Timeline

Study Start

February 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

May 15, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

May 1, 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored. Meanwhile, the dynamic molecular monitoring of neoadjuvant therapy in MIBC patients and the treatment guidance based on the MHC tumor immune microenvironment were also explored to select the treatment plan based on relevant biomarkers for subsequent immunotherapy in MIBC patients.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: not yet recruiting
Estimated enrollment: 30 participants
Study completion date: May 1, 2027
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
September 16, 2025
Actual (reported)
Study Start
February 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
First Posted
February 27, 2026
Actual (reported)
Primary Completion
May 15, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 1, 2027
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: February 27, 2026
Status Verified: February 2026
Last Update Submitted: February 25, 2026

Conditions

Muscle-invasive Bladder Cancer

Outcome Measures

Primary Outcomes (1)

pCR
The pathological complete response (pCR) rate evaluated by the pathological laboratory
immediately after the intervention/procedure/surgery

Interventions

Immunotherapy plus chemotherapyDrug

The neoadjuvant therapy regimen for muscle-invasive bladder cancer is the GC regimen. This study does not alter the patients' neoadjuvant therapy regimen but adds toripalimab to the selected neoadjuvant treatment. After MDT discussion, eligible patients will receive GC combined with immunotherapy therapy.

Also known as: Immunotherapy combined with chemotherapy

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Muscle-invasive bladder cancer

You may qualify if:

Male or female, aged ≥18 years.

Sponsors & Collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Otherlead

Biospecimen

Retention: SAMPLES WITH DNA

Blood and urine

MeSH Terms

Interventions

ImmunotherapyDrug Therapy

Intervention Hierarchy (Ancestors)

ImmunomodulationBiological TherapyTherapeutics

Study Officials

Xiongjun Ye
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
STUDY CHAIR

Central Study Contacts

Xiongjun Ye

CONTACT

13910380916 yexiongjun@cicams.cn

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 16, 2025

First Posted

February 27, 2026

Study Start

February 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

May 15, 2026

Estimated (date passed)

NCT06511648

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Phase 2Recruiting

SYFc8e67a61572c42938ce00be1dd4e2db3

EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER

Phase 2Active Not Recruiting

NCT02462239

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Not ApplicableCompleted

NCT03234153

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Phase 2Terminated

NCT03832673

Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study

Phase 2Withdrawn

NCT06957561

Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Phase 1/2Not Yet Recruiting

Expected survival ≥12 weeks.

Diagnosed by histopathology as muscle-invasive bladder urothelial carcinoma (MIBC) without upper urothelial carcinoma.

Clinical stage (cT2-T4a, N0-1, M0) and no distant metastasis as evaluated by imaging.

The subjects were assessed by urologists as tolerable and planned radical cystectomy.

ECOG Physical Condition 0-2.

You may not qualify if:

Patients with previous malignant tumors were not eligible to participate in the study unless they had achieved complete remission for at least 5 years prior to enrollment and did not require additional treatment or did not require additional treatment during the study.
Combined with serious internal medical diseases including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc.
Patients with insufficient communication, understanding and cooperation, or poor compliance, cannot be guaranteed to complete follow-up as required.

Contact the study team to confirm eligibility.

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

May 1, 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

February 27, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07440901
Data provider: ClinicalTrials.gov
Source updated: 2026-02-27
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:34:32 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record